ALBRAXIP, CIPLA PACLITAXEL, NANOPACLICIP (Cipla Australia Pty Ltd)
Product name
ALBRAXIP, CIPLA PACLITAXEL, NANOPACLICIP
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
152 working days (255)
Active ingredients
paclitaxel
Registration type
New generic medicine
Indication
Metastatic breast cancer
ALBRAXIP, CIPLA PACLITAXEL, NANOPACLICIP (powder for injection) is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.